Avilar Therapeutics

📍 Waltham, United States👥 24 employees💰 Last funded Feb 2023
Biotechnology🌐 avilar-tx.com
Website LinkedIn
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Avilar Therapeutics?
Avilar Therapeutics has 1 investors on record on gritt.io.
When did Avilar Therapeutics last raise funding?
The most recent investment in Avilar Therapeutics recorded on gritt.io was in February 2023.
What industry is Avilar Therapeutics in?
Avilar Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Avilar Therapeutics based?
Avilar Therapeutics is headquartered in Waltham, United States.